The estimated Net Worth of Ray Aspiri is at least 293 千$ dollars as of 24 October 2013. Mr. Aspiri owns over 25,000 units of Omeros stock worth over 148,326$ and over the last 15 years he sold OMER stock worth over 0$. In addition, he makes 145,170$ as Independent Director at Omeros.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Aspiri OMER stock SEC Form 4 insiders trading
Ray has made over 3 trades of the Omeros stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of OMER stock worth 178,750$ on 24 October 2013.
The largest trade he's ever made was buying 40,000 units of Omeros stock on 4 January 2013 worth over 228,800$. On average, Ray trades about 4,724 units every 71 days since 2009. As of 24 October 2013 he still owns at least 40,306 units of Omeros stock.
You can see the complete history of Mr. Aspiri stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ray Aspiri biography
Ray Aspiri serves as Independent Director of the Company. He has served on our board of directors since January 1995 and previously served as our treasurer from January 1999 to September 2007. Mr. Aspiri has also served as chairman of our compensation committee since January 1995 and as a member of our nominating and governance and audit committees since September 2009 and July 2011, respectively. From his founding of the company in 1997 until its sale in December 2012, Mr. Aspiri served as the chairman of the board of Tempress Technologies, Inc., a privately held research and development company that specialized in high-pressure fluid dynamics for the oil and gas industry. From 1980 to 1997, Mr. Aspiri served as the chairman of the board and chief executive officer of Tempress, Inc., a privately held company specializing in products for the truck, marine and sporting goods industries. Our nominating and governance committee has concluded that Mr. Aspiri should continue to serve on the board of directors based on his experience in founding and managing companies, his knowledge of commercial manufacturing and his prior experience serving on our board of directors and as chairman of our compensation committee. Mr. Aspiri has indicated an interest in potentially retiring from the board of directors before the conclusion of the term expiring at the 2022 Annual Meeting of Shareholders and has requested that we continue our ongoing search for additional director candidates to replace Mr. Aspiri should he elect to retire from our board of directors prior to the expiration of his current term.
What is the salary of Ray Aspiri?
As the Independent Director of Omeros, the total compensation of Ray Aspiri at Omeros is 145,170$. There are 9 executives at Omeros getting paid more, with Gregory Demopulos having the highest compensation of 4,825,130$.
How old is Ray Aspiri?
Ray Aspiri is 83, he's been the Independent Director of Omeros since 2007. There are no older and 30 younger executives at Omeros.
What's Ray Aspiri's mailing address?
Ray's mailing address filed with the SEC is C/O OMEROS CORPORATION, 201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119.
Insiders trading at Omeros
Over the last 15 years, insiders at Omeros have traded over 719,810$ worth of Omeros stock and bought 141,095 units worth 829,835$ . The most active insiders traders include Gregory A Md Demopulos、Marcia S. Kelbon、Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of 97,792$. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth 25,200$.
What does Omeros do?
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
What does Omeros's logo look like?
Complete history of Mr. Aspiri stock trades at Omeros
Omeros executives and stock owners
Omeros executives and other stock owners filed with the SEC include:
-
Gregory Demopulos,
Chairman of the Board, President, Chief Executive Officer -
Dr. Gregory A. Demopulos,
Co-Founder, Chairman, CEO & Pres -
Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, CEO & Pres -
Michael Jacobsen,
Chief Accounting Officer, Vice President - Finance, Treasurer -
Peter Cancelmo,
Vice President, General Counsel, Secretary -
Michael A. Jacobsen,
Chief Accounting Officer, VP of Fin. & Treasurer -
Peter B. Cancelmo J.D.,
VP, Gen. Counsel & Corp. Sec. -
Thomas Bumol,
Independent Director -
Thomas Cable,
Lead Independent Director -
Ray Aspiri,
Independent Director -
Arnold Hanish,
Independent Director -
Leroy Hood,
Independent Director -
Rajiv Shah,
Independent Director -
Peter Demopulos,
Director -
Kurt Zumwalt,
Independent Director -
Timothy Duffy,
Vice President - Business Development -
J. Steven Whitaker,
Vice President, Chief Medical Officer -
Tina Quinton,
Vice President - Patents -
Catherine Melfi,
Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer -
Bruce Meiklejohn,
Vice President - Chemistry, Manufacturing and Controls -
Daniel Kirby,
Vice President, Chief Commercial Officer -
Christopher Bral,
Vice President - Nonclinical Development -
George Gaitanaris,
Chief Scientific Officer, Vice President - Science -
Dr. J. Steven Whitaker J.D., M.D.,
VP of Clinical Devel. & Chief Medical Officer -
Dr. Pamela Pierce Palmer M.D., Ph.D.,
Co-Founder -
Nadia Dac,
Chief Commercial Officer -
Dr. Catherine A. Melfi,
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems -
Dr. J. Steven Whitaker,
VP of Clinical Devel. & Chief Medical Officer -
Peter W. Williams,
VP of HR -
Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer & VP of Science -
Dr. Pamela Pierce Palmer,
Co-Founder -
Marcia S. Kelbon,
VP Patent and General Counsel -
Diana T. Perkinson,
Director -
Daniel K Spiegelman,
Director -
Jean Philippe Tripet,
Director